mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the "mBoost" Study)
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms the mBoost Study
Most Recent Events
- 08 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 08 Dec 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Mar 2024.
- 23 Dec 2021 Status changed from recruiting to active, no longer recruiting.